Exubrion Therapeutics Promotes Gregory Taglialatela to Chief Commercial Officer
Exubrion Therapeutics has promoted Gregory Taglialatela, MBA, to Chief Commercial Officer, where he will lead the company’s commercial strategy as it continues expanding access to Synovetin OA®, its injectable treatment for canine osteoarthritis. Taglialatela assumes responsibility for national sales, key account management, business development and strategic growth initiatives effective July 1, 2026.